Exyte Partners with Univercells to Create Modular Vaccine Development Facilities

Published 5-26-2020
  • Exyte - ExyCell
  • Exyte - ExyCell
  • Exyte - ExyCell

    Courtesy of Exyte.

  • Exyte - ExyCell

    Courtesy of Exyte.

Exyte is partnering with Univercells Technologies to create modular biomanufacturing facilities to meet the increased global demand for vaccines during the SARS-CoV-2 pandemic. Exyte’s prefabricated construction system, ExyCell, is paired with Univercells’ NevoLine biomanufacturing platform which features the scale-X™ fixed-bed bioreactor at its core. ExyCell can be configured to adapt to any process layout, while the NevoLine technology presents a disruptive proven approach based on process intensification and chaining for automated, cost-effective production of large quantities of vector-based vaccines and live attenuated vaccines.

Biopharmaceutical manufacturers and vaccine developers can particularly benefit from the integrated modular system. Capital and operational expenditures are drastically reduced for the building and commissioning of GMP-compliant vaccine production plants by implementing a prefabricated solution that delivers high manufacturing capacity within a very low footprint. The units are equally suitable for use in new construction projects, renovations, or conversions. With pre-selected process equipment, the modular plant concept enables scalability for rapid capacity ramp-up and accelerated market entry, promoting the availability of vaccines for global immunization campaigns.

Related Organizations
Exyte
Designer and Engineer of Controlled Environments